| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/25/2010 | US20100048688 Dietary and pharmaceutical compositions containing carnosol and/or rosmanol and their uses |
| 02/25/2010 | US20100048687 Use of phosphatase inhibitors for the treatment of neurodegenerative diseases |
| 02/25/2010 | US20100048667 Thiolactones |
| 02/25/2010 | US20100048665 3-aminopyrrolidone derivatives |
| 02/25/2010 | US20100048663 Substituted Aryl-Indole Compounds and Their Kynurenine/Kynuramine-Like Metabolites As Therapeutic Agents |
| 02/25/2010 | US20100048656 Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders |
| 02/25/2010 | US20100048643 Novel Polymorph Forms Of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine |
| 02/25/2010 | US20100048642 Methods for treating cognitive disorders |
| 02/25/2010 | US20100048635 Use of collismycin and derivatives thereof as oxidative stress inhibitors |
| 02/25/2010 | US20100048634 Method for treating apathy syndrome |
| 02/25/2010 | US20100048630 Methods for treating cns disorders |
| 02/25/2010 | US20100048629 Methods for treating neuropathic pain |
| 02/25/2010 | US20100048628 Method for suppressing discoloration over time of adhesive preparation containing donepezil |
| 02/25/2010 | US20100048626 Aryl Substituted Pyridines and the Use Thereof |
| 02/25/2010 | US20100048623 Piperidines and related compounds for the treatment of alzheimer's disease |
| 02/25/2010 | US20100048619 Cold Menthol Receptor Antagonists |
| 02/25/2010 | US20100048602 Oligomer-Opioid Agonist Conjugates |
| 02/25/2010 | US20100048600 such as trans-2-[3'-oxospiro [cyclohexane- 1,1'(3'H)-isobenzofuran]-4yl]-5-(2-pyridyl) imidazo[4,5-b]pyridine, exhibiting neuropeptide Y antagonistic effects, used for the treatment of cardiovascular, nervous system, metabolic, gastrointestinal, sexual and respiratory system disorders; pharmacokinetics |
| 02/25/2010 | US20100048592 Use of sodium channel blockers for the management of musculoskeletal pain |
| 02/25/2010 | US20100048590 N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds |
| 02/25/2010 | US20100048589 Cold Menthol Receptor Antagonists |
| 02/25/2010 | US20100048588 Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
| 02/25/2010 | US20100048587 Cysteine and cystine bioisosteres to treat schizophrenia and reduce drug cravings |
| 02/25/2010 | US20100048583 Novel Heterocyclic NF-kB Inhibitors |
| 02/25/2010 | US20100048582 Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor |
| 02/25/2010 | US20100048575 Novel tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications |
| 02/25/2010 | US20100048574 NOVEL HETEROCYCLIC NF-kB INHIBITORS |
| 02/25/2010 | US20100048569 Diazole derivatives |
| 02/25/2010 | US20100048565 Benzimidazole derivatives |
| 02/25/2010 | US20100048558 Thienopyridines |
| 02/25/2010 | US20100048557 Triazolopyridine JAK Inhibitor Compounds and Methods |
| 02/25/2010 | US20100048555 Imidazothiazole derivatives as mark inhibitors |
| 02/25/2010 | US20100048551 Tricyclic Compounds Useful as Inhibitors of Kinases |
| 02/25/2010 | US20100048549 Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 |
| 02/25/2010 | US20100048542 Methods and compositions for treating primary and secondary tumors of the central nervous system (cns) |
| 02/25/2010 | US20100048539 Compounds and compositions as protein kinase inhibitors |
| 02/25/2010 | US20100048538 Therapeutical Uses of Eslicarbazepine |
| 02/25/2010 | US20100048537 Heteroaryl derivatives |
| 02/25/2010 | US20100048530 New 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions |
| 02/25/2010 | US20100048529 New 2-Azetidinone Derivatives Useful In The Treatment Of Hyperlipidaemic Conditions |
| 02/25/2010 | US20100048518 Pharmaceutical composition combining tenatoprazole and an anti-inflammatory agent |
| 02/25/2010 | US20100048501 Phosphorylated A2A Receptor Agonists |
| 02/25/2010 | US20100048495 Core 2 GlcNAc-T inhibitors III |
| 02/25/2010 | US20100048465 Peptide mimics of melanocyte stimulating hormone |
| 02/25/2010 | US20100048453 Oxazole and thiazole ppar modulator |
| 02/25/2010 | US20100047342 Method and Composition for Administering an NMDA Receptor Antagonist to a Subject |
| 02/25/2010 | US20100047336 Inhibition of brain enzymes involved in cerebral amyloid angiopathy and macular degeneration |
| 02/25/2010 | US20100047262 Novel method for down-regulation of amyloid |
| 02/25/2010 | US20100047247 Nerve elongation promoter and elongation inhibitor |
| 02/25/2010 | US20100047233 Treatment of post-menopausal and post-hysterectomy mediated cognitive disorders |
| 02/25/2010 | US20100047232 Modulators of neuronal regeneration |
| 02/25/2010 | US20100047220 Substances |
| 02/25/2010 | US20100047218 Reversible immortalization |
| 02/25/2010 | US20100047211 Method of growth of mesenchymal cells under non-adherent conditions for clinical applications |
| 02/25/2010 | US20100047179 Targeted split biomolecular conjugates for the treatment of diseases, malignancies and disorders, and methods of their production |
| 02/25/2010 | US20100047177 treating or preventing axonal degradation in neuropathic diseases in mammals; axonopathy; administering an agent that increases AMP activated kinase (AMPK), LKB1 and CaMKK beta acitvity in diseased and/or injured neurons and supporting cells in an amount effective to decrease axonal degeneration |
| 02/25/2010 | DE102008038221A1 7-Azaindolderivate 7-azaindole derivatives |
| 02/25/2010 | DE102008038220A1 Oxadiazolderivate Oxadiazole |
| 02/25/2010 | CA2735050A1 Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof |
| 02/25/2010 | CA2734972A1 An extended release pharmaceutical composition of entacapone or salts thereof |
| 02/25/2010 | CA2734866A1 Complement inhibitors for treatment of injury from intracerebral hemorrhage |
| 02/25/2010 | CA2734859A1 Methods for treating cns disorders |
| 02/25/2010 | CA2734797A1 Treatment of anxiety disorders |
| 02/25/2010 | CA2734720A1 Hydroxybutyrate ester and medical use thereof |
| 02/25/2010 | CA2734585A1 Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies |
| 02/25/2010 | CA2734578A1 Antibodies to ccr2 |
| 02/25/2010 | CA2734237A1 Treatment of stroke using isolated placental cells |
| 02/25/2010 | CA2733790A1 Macrocyclic compounds for inhibition of tumor necrosis factor alpha |
| 02/25/2010 | CA2733508A1 Compounds for the treatment of peripheral neuropathies |
| 02/25/2010 | CA2732969A1 Novel compounds and their uses in diagnosis |
| 02/24/2010 | EP2157092A1 Remedy for diabetes |
| 02/24/2010 | EP2156863A2 Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors |
| 02/24/2010 | EP2156862A1 Use of digitalis-like compounds in the treatment of affective disorders |
| 02/24/2010 | EP2156839A1 Method of treating movement disorders using barbituric acid derivatives |
| 02/24/2010 | EP2156838A1 Method for producing pharmaceutical tablet |
| 02/24/2010 | EP2156837A1 Crystalline micropowder particles |
| 02/24/2010 | EP2156833A1 Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient |
| 02/24/2010 | EP2156831A1 Augmented Cognitive Training |
| 02/24/2010 | EP2156828A1 Method and dosage regimens for eliminating a chemical substance in blood |
| 02/24/2010 | EP2155749A1 Pyrrolopyridine derivatives and their use as bace inhibitors |
| 02/24/2010 | EP2155747A1 Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors |
| 02/24/2010 | EP2155745A1 6-(pyrrolopyridinyl)-pyrimidine-2-yl-amine derivatives |
| 02/24/2010 | EP2155744A1 Heteroaryl amide analogues as p2x7 antagonists |
| 02/24/2010 | EP2155740A1 Hetarylanilines as modulators for amyloid beta |
| 02/24/2010 | EP2155737A1 Gamma secretase modulators |
| 02/24/2010 | EP2155736A1 Novel carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound |
| 02/24/2010 | EP2155731A1 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase |
| 02/24/2010 | EP2155729A1 Prolinamide-tetrazole derivatives as nk3 receptor antagonists |
| 02/24/2010 | EP2155727A1 N-[6-amino-5-(phenyl)pyrazin-2-yl]-isoxazole-4-carboxamide derivatives and related compounds as nav1.8 channel modulators for the treatment of pain |
| 02/24/2010 | EP2155726A1 Phthalazinone derivatives and their use as medicament to treat cancer |
| 02/24/2010 | EP2155719A1 Azacyclylbenzamide derivatives as histamine-3 antagonists |
| 02/24/2010 | EP2155717A1 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines and pyridines and 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl pyridines as 5-ht7 receptor antagonists |
| 02/24/2010 | EP2155707A1 Metabolites of (thio)carbamoyl-cyclohexane derivatives |
| 02/24/2010 | EP2155696A2 Piperazine salts as d3/d2 antagonists |
| 02/24/2010 | EP2155674A1 Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands |
| 02/24/2010 | EP2155672A1 Prolinamide derivatives as nk3 antagonists |
| 02/24/2010 | EP2155671A2 New disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission |
| 02/24/2010 | EP2155669A1 New disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission |
| 02/24/2010 | EP2155668A2 Crystalline forms of (r)-1-{2-ý4'- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl¨-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto |
| 02/24/2010 | EP2155335A1 Pharmaceutical composition, use of the pharmaceutical composition for treating a brain tumor, production process thereof and a kit of parts comprising the pharmaceutical composition |